drugset / Trial / NCT00344981

Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral Suppression

NCT00344981

Completed 9 enrolled University of Maryland, Baltimore
RandomizedParallel-groupOpen-labelTreatment

Summary

Study Hypothesis Evaluation of the durability of the combination Tenofovir and Hydroxyurea to maintain viral suppression below 50 copies/ml in volunteers who have achieved viral suppression on a standard HAART regimen.

Timeline

Start
2003-06
Primary completion
2006-11
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxyurea Other / unclassified 500 mg
Subject Tenofovir Small molecule 300 mg

Indications